Daiichi Sankyo Authorizes the First YESCARTA® (Axicabtagene Ciloleucel) CAR T-cell Therapy Treatment Site in Japan

Got To Article
Kite, a Gilead Company, and Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that YESCARTA ® (axicabtagene ciloleucel), a chimeric antigen receptor (CAR) T-cell therapy, will be available to patients with relapsed or refractory large B-cell lymphomas in Japan through the first treatment center now authorized by Daiichi Sankyo.
0 comments

A Letter from Chief Operating Officer Daniel Alegre Regarding Activision Blizzard’s 2021 Representation Data

Got To Article
Activision Blizzard, Inc. (Nasdaq: ATVI) President and Chief Operating Officer Daniel Alegre today sent the following letter to employees showing the company’s current data on global gender and US diverse representation,
0 comments